ALK-Positive Lung Adenocarcinoma Arising in an Adolescent Treated for Relapsed Neuroblastoma
Yazeed Alwelaie(University of British Columbia), Anna F. Lee(University of British Columbia), Rebecca Deyell(University of British Columbia), Shahrad R. Rassekh(Great Ormond Street Hospital), Janessa Laskin(BC Cancer Agency), Chen Zhou(Jiangnan University), Helen Nadel(Helios Klinikum Emil von Behring), Tracy Tucker(BC Cancer Agency), John C. English(University of British Columbia Hospital)
Cited by 3
Related Papers
Probability of Cancer in Pulmonary Nodules Detected on First Screening CT
|New England Journal of Medicine|2013|1.4k
Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase 2B, open-label, randomised controlled trial
|The Lancet Oncology|2016|1.2k
Efficacy of Selpercatinib in <i>RET</i> -Altered Thyroid Cancers
|New England Journal of Medicine|2020|766
Methotrexate, Doxorubicin, and Cisplatin (MAP) Plus Maintenance Pegylated Interferon Alfa-2b Versus MAP Alone in Patients With Resectable High-Grade Osteosarcoma and Good Histologic Response to Preoperative MAP: First Results of the EURAMOS-1 Good Response Randomized Controlled Trial
|Journal of Clinical Oncology|2015|419